PHOENIX--(BUSINESS WIRE)--Zila, Inc. (Nasdaq GM: ZILA) has completed the divestiture of its wholly-owned subsidiary Zila Nutraceuticals, Inc. for a total cash transaction of $37.5 million with up to an additional $3 million to be paid through an earn-out formula dependent upon the future performance of the business. Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and Ester-E(R), was purchased by NBTY, Inc. (NYSE: NTY). The sale is consistent with Zila’s strategy of focusing its business on cancer detection technologies and divesting its non-core assets.
